icg-001 and Kidney-Diseases

icg-001 has been researched along with Kidney-Diseases* in 2 studies

Other Studies

2 other study(ies) available for icg-001 and Kidney-Diseases

ArticleYear
Promotion of β-catenin/Foxo1 signaling ameliorates renal interstitial fibrosis.
    Laboratory investigation; a journal of technical methods and pathology, 2019, Volume: 99, Issue:11

    Transforming growth factor β (TGF-β) is the key cytokine involved in causing fibrosis through cross-talk with major profibrotic pathways. However, inhibition of TGF-β to prevent fibrosis would also abrogate its anti-inflammatory and wound-healing effects. β-catenin is a common co-factor in most TGF-β signaling pathways. β-catenin binds to T-cell factor (TCF) to activate profibrotic genes and binds to Forkhead box O (Foxo) to promote cell survival under oxidative stress. Using a proximity ligation assay in human kidney biopsies, we found that β-catenin/Foxo interactions were higher in kidney with little fibrosis, whereas β-catenin/TCF interactions were upregulated in the kidney of patients with fibrosis. We hypothesised that β-catenin/Foxo is protective against kidney fibrosis. We found that Foxo1 protected against rhTGF-β1-induced profibrotic protein expression using a CRISPR/cas9 knockout of Foxo1 or TCF1 in murine kidney tubular epithelial C1.1 cells. Co-administration of TGF-β with a small molecule inhibitor of β-catenin/TCF (ICG-001), protected against kidney fibrosis in unilateral ureteral obstruction. Collectively, our human, animal and in vitro findings suggest β-catenin/Foxo as a therapeutic target in kidney fibrosis.

    Topics: Animals; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Disease Models, Animal; Fibrosis; Forkhead Box Protein O1; Gene Knockout Techniques; Hepatocyte Nuclear Factor 1-alpha; Humans; Kidney; Kidney Diseases; Male; Mice; Pyrimidinones; Signal Transduction; Transforming Growth Factor beta1

2019
Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis.
    Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:9

    Because fibrotic kidneys exhibit aberrant activation of β-catenin signaling, this pathway may be a potential target for antifibrotic therapy. In this study, we examined the effects of β-catenin activation on tubular epithelial-mesenchymal transition (EMT) in vitro and evaluated the therapeutic efficacy of the peptidomimetic small molecule ICG-001, which specifically disrupts β-catenin-mediated gene transcription, in obstructive nephropathy. In vitro, ectopic expression of stabilized β-catenin in tubular epithelial (HKC-8) cells suppressed E-cadherin and induced Snail1, fibronectin, and plasminogen activator inhibitor-1 (PAI-1) expression. ICG-001 suppressed β-catenin-driven gene transcription in a dose-dependent manner and abolished TGF-β1-induced expression of Snail1, PAI-1, collagen I, fibronectin, and α-smooth muscle actin (α-SMA). This antifibrotic effect of ICG-001 did not involve disruption of Smad signaling. In the unilateral ureteral obstruction model, ICG-001 ameliorated renal interstitial fibrosis and suppressed renal expression of fibronectin, collagen I, collagen III, α-SMA, PAI-1, fibroblast-specific protein-1, Snail1, and Snail2. Late administration of ICG-001 also effectively attenuated fibrotic lesions in obstructive nephropathy. In conclusion, inhibiting β-catenin signaling may be an effective approach to the treatment of fibrotic kidney diseases.

    Topics: beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; CREB-Binding Protein; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Humans; Kidney Diseases; Pyrimidinones; Smad Proteins; Transforming Growth Factor beta1

2011